Abnormal iron parameters in the pregnancy syndrome preeclampsia by Rayman, MP et al.
 1
Abnormal iron parameters in the pregnancy syndrome pre-eclampsia 
 
Margaret P. Rayman, DPhil (Oxon)1  
John Barlis, MSc1  
Robert W. Evans, PhD2  
Christopher W. G. Redman, MD3  
Laurence J. King, PhD1 
 
1Guildford, Surrey, UK 
2London, UK 
3Oxford, Oxfordshire, UK 
 
1 University of Surrey, School of Biomedical and Life Sciences 
2 King’s College London, Guy’s Campus, Division of Biomolecular Sciences, Metalloprotein 
Research Group  
3 University of Oxford, Nuffield Department of Obstetrics and Gynaecology, John Radcliffe 
Hospital 
 
Reprints and correspondence 
Dr. Margaret P. Rayman, School of Biomedical and Life Sciences, University of Surrey, 
Guildford GU2 7XH, UK 
Business telephone number  (44) 1483 686447 
Home telephone number (44) 1483 562882 
Fax number   (44) 1483 686481 
Condensation  
 2
Iron release, sometimes sufficient to cause iron overload, occurs in pre-eclampsia, decreasing 
the antioxidant capacity of serum and exacerbating lipid peroxidation and endothelial-cell 
injury. 
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Abnormal iron parameters in the pregnancy syndrome pre-eclampsia 
Margaret P. Rayman, DPhil (Oxon)1, John Barlis, MSc1, Robert W. Evans, PhD2, Christopher 
W. G. Redman, MD3, Laurence J. King, PhD1 
OBJECTIVE: To investigate iron status parameters in pre-eclampsia with a view to 
exploring their possible contribution to the etiology. 
STUDY DESIGN: In prepared serum samples from 40 pre-eclamptic women and matched 
pregnant controls at the John Radcliffe Hospital, Oxford, a number of iron status parameters 
were measured.  Statistical analysis was by Wilcoxon’s Signed Rank Test and linear 
regression. 
RESULTS: Serum iron concentration, ferritin and percent saturation of transferrin were 
significantly higher in the pre-eclamptic patients than in controls, whereas unsaturated iron-
binding capacity and apotransferrin levels were significantly lower.  No difference was found 
in hemopexin concentrations in the two groups.  Gestational age at the time of sampling was 
correlated (positively) with only two parameters: TIBC and UIBC, but only in the pre-
eclampsia group.  Eighteen percent of pre-eclamptic subjects had percent transferrin 
saturation levels in the region associated with iron overload.  
CONCLUSION: Released iron species in pre-eclampsia may contribute to the etiology and 
will exacerbate lipid peroxidation and endothelial-cell injury.   Given the high prevalence of 
heterozygosity for haemochromatosis with the associated reduced ability to exclude ingested 
iron, it may be appropriate to consider the advisability of giving iron supplements to pregnant 
women at high risk of pre-eclampsia, in the absence of evidence of iron deficiency. 
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Pre-eclampsia is a disorder which is believed to affect one in ten of all pregnancies to 
some degree.  It is the biggest single cause of maternal and fetal mortality and currently there 
is no cure other than termination of the pregnancy.1 
 The causes of pre-eclampsia are complex and are not fully understood but the 
condition may be associated with poor placentation.2  Placentation is complete by about 18 
weeks of pregnancy long before symptoms and signs of pre-clampsia become apparent.  It is 
however not known if poor placentation underlies all cases without exception.2  The effect of 
poor placentation is to leave the spiral arteries smaller than normal for the second half of 
pregnancy.2  It is assumed that this and the associated obstructive lesion of the spiral arteries 
called acute atherosis lead to placental ischemia for which there is considerable evidence 
(summarized in Redman and Sargent3).  A causal sequence of events in pregnant women 
cannot be proved.  It is possible that pre-eclampsia causes placental ischemia although more 
likely that placental ischemia causes pre-eclampsia especially as poor placentation is an early 
preclinical development.  Moreover pre-eclampsia-like syndromes can be induced in 
pregnant animals by surgical restriction of the uteroplacental blood supply.4  It is presumed 
that blood-borne agents arising from the ischemic placenta are the cause of the generalised 
endothelial-cell damage which gives rise to the symptoms of hypertension, proteinuria, and 
sudden edema, characteristic of this condition.5  The high levels of circulating lipid 
hydroperoxides believed to be present in pre-eclampsia are among the candidate agents 
capable of causing such damage to the vascular endothelium.6  The malperfused placenta 
may be responsible for the generation of these reactive chemical species. 
 When tissues become ischemic, reactive oxygen species such as superoxide and 
hydrogen peroxide are produced, but neither of these is reactive enough to initiate cellular 
damage directly.7  However, in the presence of catalytic amounts of transition metal ions, 
particularly iron, which may arise in the ischemic placenta by destruction of red blood cells 
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from thrombotic, necrotic and hemorrhagic areas,8,9 these species can generate the highly 
reactive hydroxyl radical by Fenton chemistry (Figure 1).7,10  This radical can initiate the 
process of lipid peroxidation which, if uncontrolled, may result in endothelial-cell damage, as 
hypothesized by Hubel and colleagues.6 
Extracellular hemoglobin can also support lipid peroxidation either through prior iron 
release or release of heme from methemoglobin.9,10  Free heme can generate lipid 
hydroperoxides in low density lipoprotein (LDL) particles 11 or diffuse into membranes of 
endothelial cells causing peroxidative damage and cytotoxicity.12  Even minimal vascular 
hemolysis is sufficient to yield hemoglobin at a concentration range that can affect LDL 
peroxidation. 
 Protection from these deleterious pro-oxidative effects in the plasma is normally 
afforded by proteins that bind these iron entities in a relatively inert state.  Plasma iron is 
usually almost entirely safely bound to the transport protein transferrin.  The greater the 
extent to which transferrin is saturated with iron, the lower the antioxidant capacity of the 
plasma.13  Iron released intracellularly is normally safely sequestered in ferritin and serum 
ferritin reflects the amount of the storage protein.14 
 The plasma proteins haptoglobin, hemopexin and albumin, bind free hemoglobin and 
heme, affording protection against iron- and heme-catalysed lipid peroxidation and 
endothelial-cell injury.10  Elevated heme catabolism occurs in pre-eclampsia as shown by 
increased levels of bilirubin and carboxyhemoglobin.8  Although hemopexin is clearly an 
important extracellular antioxidant,15 its possible importance in the pre-eclampsia syndrome 
has been previously overlooked. 
 Disturbances in iron homeostasis have already been observed in pre-eclampsia.8,13,16,17  
It was decided to investigate further the possible importance of such factors in the condition 
and to look for the first time at hemopexin levels.  This study therefore compares a number of 
 6
iron parameters, including hemopexin, serum ferritin and the extent to which transferrin is 
saturated with iron, in pre-eclamptic women and matched pregnant controls. 
 
Material and methods 
 Forty obstetric patients at the John Radcliffe Hospital, Oxford, identified as suffering 
from pre-eclampsia according to specific criteria (new hypertension, from below to 
consistently at or above 90 mm Hg diastolic pressure; new proteinuria ≥ 75 mg / mmol 
creatinine, in the absence of urinary-tract infection), were each matched with a healthy 
pregnant woman of the same age ± 4 years, the same gestation ± 13 days and the same parity 
group namely 0, 1-3 or ≥4.  All controls had conceived spontaneously, had never received a 
blood transfusion and were not on any medication. .  The pre-eclamptic patients received 
treatment for their blood pressure, methyl dopa and/or nifedipine.  Neither pre-eclamptic nor 
control women received iron supplements.  Serum was prepared from venous blood collected 
from these women and stored at -400C until analyzed.  The mean gestational age at the time 
of blood sampling was 33 weeks.  Samples were obtained in two sets of 20 pairs in 
consecutive years.  Ferritin was determined only in the first set of 20 pairs, while an 
electrophoretic technique not initially available to us, was applied only to the second set of 
20 pairs, to determine percent-transferrin-saturation, apotransferrin and hemopexin.  One 
control sample from the first set was lost giving 19 pairs for statistical analysis. 
The clinical characteristics recorded were:- age, gestational age at the time of blood 
sampling, systolic and diastolic blood pressure, proteinuria, platelet count, aspartate 
aminotransferase (AST) activity (an indicator of liver damage), gestational age at the time of 
delivery, infant sex and birth weight. 
The study was approved by Central Oxford Research Ethics Committee.  
 Serum total iron and unsaturated iron binding capacity (UIBC) were measured on a 
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Cobas Mira Plus automatic analyzer (Roche Diagnostic Systems, Hertfordshire, UK) at the 
University of Surrey using a colorimetric method (Unimate 5 iron and Unimate 7 UIBC kits, 
Roche Products).  Accuracy and precision were verified for serum total iron, by analysis of 
control serum N (Roche Products) and a lyophilized second-generation human serum 
certified reference material supplied from the lab of Versieck and co-workers (University of 
Ghent, De Pintelaan 185, B-9000 Ghent, Belgium), while for UIBC, control serum N was 
used. 
Determination of iron concentration in control serum N gave a mean and standard 
deviation of 14.15 ± 0.25 µmol/l (certified mean 14.00 µmol/l), coefficient of variation 1.8 
and 95% confidence interval 14.02 - 14.29.  Iron analysis of the certified reference serum 
gave a mean and standard deviation of 40.57 ± 0.94 µmol/l (certified mean 42.16 µmol/l), 
coefficient of variation 2.3 and 95% confidence limits 39.90 - 41.24 µmol/l (certified serum 
39.72 - 44.60 µmol/l).  These results demonstrate the acceptable accuracy of the iron assay 
method. 
 Total iron binding capacity (TIBC) was calculated as the sum of the serum iron and 
UIBC.  The percentage saturation of iron binding capacity was calculated as: serum iron x 
100/TIBC. 
 Percent transferrin saturation was also determined by urea-polyacrylamide gel 
electrophoresis.18  This method separates transferrin into the apo-, the two monoferric forms 
and the diferric form, according to their electrophoretic mobilities.  To enable detection of the 
four transferrin bands, serum samples were treated before being applied to the gel with 6,9-
diamino-2-ethoxyacridine lactate (Sigma Chemical Co., UK) to precipitate all serum proteins 
but β- and γ-globulins.  On completion of the electrophoretic run, the gel was stained for 20 
min and then repeatedly destained until the background was clear.  The relative amounts of 
the transferrin components were determined by densitometry using the Oast Tech computer 
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package gel analysis system (Oast Tech, Gillingham, Kent, UK).  Percent transferrin 
saturation was calculated as follows:- 
 
% transferrin saturation  =   [(C-monoferric) + (N-monoferric) + (2 x diferric)]     x 100 
 2(apo + C-monoferric + N-monoferric + diferric) 
 
Relative apotransferrin concentrations in the two patient groups were also obtained by this 
method. 
There is no hemopexin assay commercially available in the UK.  The possibility of 
determining hemopexin by the same electrophoretic technique as used for the different forms 
of transferrin was investigated.  A purified hemopexin preparation (Bio Products Lab., 
Borehamwood, Herts., UK) containing 19% heme-hemopexin and 81% apohemopexin was 
used to ascertain the feasibility of this method.  A single band was seen between those of the 
monoferric forms of transferrin and the diferric form, suggesting either that heme-hemopexin 
and apohemopexin have the same electrophoretic mobility in the urea-polyacrylamide gel or, 
more likely, that under the conditions of the electrophoretic separation, the heme-hemopexin 
complex dissociates.  The band was quantified by densitometry as for the different forms of 
transferrin. 
 Serum ferritin was determined by a microparticle enzyme immunoassay method using 
the Abbott AxSYM system (Abbott Laboratories, Diagnostics Division, Maidenhead, UK).  
The recommended quality control procedures of the manufacturer were carefully followed. 
Data Analysis.  Owing to some extremely high values, parametric statistical methods 
appropriate for normally-distributed data were precluded.  Wilcoxon’s Signed Rank Test for 
non-parametric, paired data was used to compare iron parameters in the pre-eclamptic 
patients and their matched controls.   Infant birth weights were allocated to centiles using 
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“Oxford Standards” charts (Castlemead, Ware, Herts., UK), allowing correction for length of 
gestation and sex.  The χ2 test was then applied to compare the frequency distribution of 
centile birth weights in the pre-eclamptic and control groups.   Linear regression analysis was 
used to identify possible correlations between the different iron parameters measured and the 
clinical data (e.g. gestational age, AST activity, platelet count, systolic or diastolic blood 
pressure).  For all tests significance was accepted for p < 0.05.  
 
Results 
 The pre-eclamptic patients were all suffering from a fairly severe to very severe level 
of the disease.  Ten had AST levels > 42 IU/l suggesting a component of liver damage while 
thirteen had a low platelet count (< 175x109 cells/l), also indicative of disease severity, 
though two control subjects also had a platelet count in this range.  Seven of the pregnancies 
were complicated by the HELLP (hemolysis, elevated liver enzymes, low platelets) or ELLP 
(elevated liver enzymes, low platelets) syndromes.  Gestational age at delivery and centile 
infant birth weights (corrected for length of gestation and sex) were significantly lower (p < 
0.0001 and 0.001 respectively) in the pre-eclamptic group, the latter indicating some fetal-
growth retardation.  Median hematocrit did not differ between the groups. 
 For all parameters measured, results, including maximum and minimum values and 
interquartile ranges, are summarized in Table 1.   
Median serum iron concentration was around 1.7 fold higher in patients with pre-
eclampsia than in pregnant controls (21.7 vs 12.9 µmol/l; p < 0.001).  Results are shown 
graphically in Figure 2.  Of the pre-eclamptic subjects, four had very high values for serum 
iron (43.7 – 79.3 µmol/l) and their AST levels indicated liver damage.  Omission of these 
subjects from the analysis reduced the ratio of the median serum iron concentrations from 1.7 
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to 1.5 (p < 0.001). 
 Both UIBC and TIBC were significantly lower in the pre-eclamptic patients than in 
the matched controls (47.5 vs 68.7 µmol/l; p < 0.0001) and (75.5 vs 85.7 µmol/l; p < 0.0001) 
respectively. 
Median percent saturation of iron-binding capacity (colorimetric method) in women 
with pre-eclampsia was twice as high as that of matched controls (32.2% vs 15.9 % ; p < 
0.0001).  Four pre-eclamptic subjects with elevated AST levels had values for percent 
saturation of iron-binding capacity of 50-100%.  Even when these subjects were excluded 
from the analysis, iron-binding capacity was still 1.8 times more saturated in the pre-
eclamptic patients than in controls.  Seven of 40 pre-eclamptic patients (18%) had percent 
saturation levels in the range associated with iron overload states (50-100%).14  Percent 
saturation of transferrin (electrophoretic method), was more than twice as high in the pre-
eclampsia group as in the normal-pregnancy group (median: 27.6 % vs 11.6%; p<0.0001).  
Two of 20 pre-eclamptic patients (10%) had percent saturation levels in the range associated 
with iron overload states.   
Since transferrin is by far the most important iron binding protein in serum,19 
determination of the percent saturation of iron binding capacity as measured by the 
colorimetric method is to a good approximation a determination of the percent saturation of 
transferrin as obtained directly by gel electrophoresis.  Indeed there was a highly significant 
correlation, between the two methods for both patient groups (r = 0.94 for combined data; 
p<0.0001). 
Apotransferrin level measured in arbitrary units was significantly lower in pre-
eclampsia patients than in matched pregnant controls (289 vs 530; p<0.0001).  
Hemopexin level measured in arbitrary units in the pre-eclampsia group did not differ 
significantly from the hemopexin level in the normal pregnancy group (257 vs 237). 
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 Median serum ferritin was around six-fold higher in the pre-eclamptic patients than in 
the matched pregnant controls (53.1 vs 9.4 µg/l; p<0.001) as shown graphically in Figure 3.  
Three out of four subjects with very high ferritin levels (257-1259 µg/l) had AST values  
> 42 IU/l, suggesting a component of liver damage.  When those subjects were excluded 
however, the median ferritin level was still about five-fold higher. 
No significant correlations were found between serum iron, TIBC, UIBC, 
apotransferrin, hemopexin, ferritin or any of the iron saturation parameters and indices of 
hepatocellular injury (AST), coagulopathy (platelet count), and cardiovascular system 
abnormalities (diastolic and systolic blood pressure) in the pre-eclamptic patients, with the 
exception of a weakly significant positive correlation between UIBC and platelet count (r = 
0.55, p = 0.03).  
Gestational age at the time of sampling was correlated (positively) with only two 
parameters: TIBC (r = 0.71, p = 0.0005; and UIBC (r = 0.53, p = 0.015) in the pre-eclampsia 
group.  No such correlation was apparent in the control group (TIBC, r = 0.30, ns; UIBC, r = 
0.27, ns). 
 
Comment 
The colorimetric and electrophoretic methods used to gauge the extent of transferrin 
saturation with iron in our subjects gave results which were very significantly correlated and 
indicated that transferrin saturation in the pre-eclamptic patients was double or more, that in 
the controls.  This reflects the significantly higher serum iron (by 68%) and significantly 
lower total iron binding capacity, TIBC (by 12%), of the pre-eclamptic subjects compared to 
the controls.  Seven of the 40 pre-eclamptic subjects (18%), had percent saturation levels 
within the range associated with iron overload.14 
 Unsurprisingly, UIBC, being inversely related to percent transferrin saturation, was 
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significantly decreased (by 31%) in the pre-eclamptic group relative to the control group.  
This suggests that pre-eclamptic women only have around two-thirds of the capacity of 
controls to bind additional iron.  UIBC reflects the concentrations of both apotransferrin and 
mono-ferric transferrin species.  Apotransferrin alone, measured by the electrophoretic 
method, was decreased even further than UIBC - by 45% - in the pre-eclamptic group relative 
to the control group, reflecting the decreased likelihood of finding any iron-free transferrin at 
the much-higher iron concentrations existing in this group.  
Our findings on iron, UIBC, TIBC and % saturation of iron-binding capacity are in 
agreement with those of previous studies.8,13,16,17  The lack of correlation between serum iron 
and AST levels reflects the poor correlation with parameters of hepatocellular injury found 
previously16,17 and suggests that the raised iron levels cannot be explained by liver damage. 
Hemopexin levels, monitored as an indirect measure of whether heme release could 
be a factor in stimulating lipid peroxidation, were not significantly different in pre-eclamptic 
patients and their normal pregnant controls.  As levels of hemopexin do not always decrease 
in states of intravascular hemolysis,20 there remains the possibility of some release of heme 
into the circulation in pre-eclampsia, particularly as increased levels of heme metabolites are 
certainly observed.8   Furthermore, since it was not possible to separate apohemopexin and 
heme-hemopexin on the urea-polyacrylamide gel, a difference in the heme bound would not 
have been detected. 
Previous studies have come to different conclusions about whether ferritin levels are 
raised in pre-eclampsia.16,17   In our study, even when the three subjects with very high ferritin 
and AST values were excluded from the analysis, the median ferritin level was still around 
five-fold higher in the pre-eclamptic group and no correlation was found between serum 
ferritin and AST levels.  This suggests that liver damage is not the principal source of the 
raised ferritin levels in most subjects, corroborating previous findings.21  Ferritin is an acute-
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phase protein.  The highest levels of ferritin, an acute phase protein, were not found in 
subjects with the lowest albumin levels, suggesting that an acute-phase response was not 
responsible for the raised serum ferritin.  Serum ferritin was not correlated with serum iron, 
in line with findings from previous workers.21 
Gestational age at the time of sampling was significantly and positively correlated 
with TIBC and weakly with UIBC, but only in the pre-eclampsia group.  This correlation was 
not observed in the control group though it might have been expected as a response to falling 
iron levels as the pregnancy progressed.22  Hubel and colleagues did not observe a correlation 
between TIBC and gestational age in pre-eclampsia.13   We cannot explain our findings or the 
difference between the two studies, except to postulate that a mechanism may exist for 
increasing transferrrin expression in response to oxidative stress. 
Origin of increased serum iron.  The lack of correlation with parameters of liver 
injury in this and other studies eliminates the liver as the probable source of iron.20  However, 
data are consistent with a rise in heme catabolism following increased destruction of maternal 
red cells8,13,16,17 and a nine-times greater level of hemoglobin in the serum of pre-eclamptic 
than control subjects has been reported.17  
The pre-eclamptic placenta presents a histological picture of severe vascular damage 
in decidual vessels adjacent to infarcted areas,23 consistent with cell injury and release of 
iron.  Injured red blood cells from necrotic and hemorrhagic areas of infarcted or ischemic 
placental tissue may be a primary source of potentially toxic iron through the release of 
hemoglobin or heme into the system.8,9   
Is iron involved in the etiology of pre-eclampsia?  Oxidative stress in pre-eclampsia 
correlated inversely with UIBC and positively with % transferrin saturation.13  This implies 
that iron (or an iron species) could be a factor in the generation of the oxidative stress of the 
condition.  Even at very low concentrations, iron entities such as hemoglobin and heme can 
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increase LDL oxidation,11 suggesting a further mechanism by which iron might be involved 
in the etiology of the condition.  The ability of vitamins C and E to decrease LDL oxidation 
might explain their effectiveness in reducing the risk of pre-eclampsia.24 
The damaged placenta is a likely site for the production of free radicals in pre-
eclampsia.  Iron species released there from red-cell destruction are clearly capable of 
initiating and propagating lipid peroxidation25 both in the placenta and in the vasculature, and 
may be a significant etiological factor in the endothelial-cell damage of pre-eclampsia. 
Conclusion.  This work has highlighted a significant deficit in the antioxidant 
capacity of serum by decreased serum-iron buffering in pre-eclampsia.  Released iron species 
may be implicated in the etiology of the condition, but at the very least, are likely to increase 
oxidative stress, exacerbate lipid peroxidation and promote endothelial-cell injury. 
We concur with the previous suggestion22 that raised serum iron and ferritin may have 
the potential to be used diagnostically to warn of incipient pre-eclampsia. 
Eighteen percent of our pre-eclamptic subjects had transferrin saturation levels in the 
region associated with iron overload.  It is now known that as many as 38% of the population 
are at increased risk of iron overload owing to mutations in the HFE gene associated with 
haemochromatosis.26 
Given the prevalence of heterozygosity for hemochromatosis with the associated 
reduced ability to exclude ingested iron,26,27 and the proportion of our pre-eclamptic subjects 
with iron overload, it may be appropriate to consider the advisability of giving iron 
supplements to pregnant women at high risk of pre-eclampsia, in the absence of evidence of 
iron deficiency.  While there is no suggestion that iron supplements are the cause of the 
excess iron seen in pre-eclampsia, they could be an exacerbating factor in women susceptible 
to iron overload.  Accordingly, the same strictures would apply to the use of parenteral iron. 
Genetic evaluation of mutations in the HFE gene in a larger study of such women would be 
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of interest. 
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Table I.  Serum iron parameters in pre-eclamptic patients and matched pregnant control 
subjects 
 
  Median   Interquartile Min / max p value 
Serum iron (µmol/l) Control 12.9 10.0 - 19.7 4.3 / 39.0  
 Pre-ecl 21.7 15.9 - 32.6 6.3 / 79.3 <0.001 
UIBC (µmol/l) Control 68.7 61.6 - 87.0 46.7 / 117.1  
 Pre-ecl 47.5 34.3 - 62.6 0.3 / 94.3 <0.0001 
TIBC (µmol/l) Control 85.7 80.5 - 97.8 68.7 / 121.4  
 Pre-ecl 75.5 62.6 - 82.7 39.3 / 106.8 <0.0001 
% saturation  Control 15.9 10.9 - 23.8 3.5 / 42.1  
(colorimetric method) Pre-ecl 32.2 21.1 - 47.4 7.3 / 99.6 <0.0001 
% saturation  Control 11.6 8.7 - 16.0 3.2 / 37.3  
(electrophor. method) Pre-ecl 27.6 15.8 - 38.9 10.8 / 73.7 <0.0001 
Apotransferrin  Control 530 409 - 684 241 / 809  
(arbitrary units) Pre-ecl 289 194 - 458 27 / 639 <0.0001 
Serum haemopexin Control 237 202 - 317 122 / 505  
(arbitrary units) Pre-ecl 257 200 - 316 117 / 471 ns 
Serum ferritin (µg/l) Control 9.4 7.7 - 12.2 5.3 / 43.5  
 Pre-ecl 53.1 22.7 - 66.1 8.7 / 1260 <0.001 
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Figure legends 
Fig. 1. Iron-catalysed initiation and propagation of lipid peroxidation  
 
Fig. 2.  Scatterplot of serum iron concentrations in pre-eclamptic women and matched 
pregnant controls.  Horizontal bars represent the median values. 
  
Fig. 3.  Scatterplot of serum ferritin concentrations in pre-eclamptic women and matched 
pregnant controls.  Horizontal bars represent the median values. 
N.B. The four values off-scale in the pre-eclampsia group were all > 250 µg/l.
Initiation 
Iron-catalysed Haber-Weiss Reaction   
 Fe(III) +  O2•-
      ∏  O2    +  Fe(II) 
 Fe(II)   +  H2O2    ∏   Fe(III)  +  OH-  +   OH•          Fenton reaction 
The source of hydrogen peroxide for the Fenton reaction is the dismutation of superoxide 
which is likely to be catalysed by superoxide dismutase (SOD). 
    SOD  
 2O2•-   +   2H+    ∏   H2O2   +   O2    
 
Propagation 
Iron (II) and certain iron (II) chelates react with lipid hydroperoxides (ROOH), as with 
hydrogen peroxide, splitting the O-O bond.  This gives RO•, an alkoxyl radical, which can 
also abstract H• from polyunsaturated fatty acids and from hydroperoxides.  The resulting 
peroxyl radicals ROO• can continue propagation of lipid peroxidation. 
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